Japanese pharma major Takeda (TYO: 4502) has presented positive results from its Phase IIb trial of TAK-861 at the SLEEP 2024 annual meeting.
The firm is testing the therapy in narcolepsy type 1 (NT1), a chronic, rare neurological central disorder.
NT1 is caused by a significant loss of orexin neurons, and there are currently no approved treatments targeting the underlying pathophysiology of the condition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze